Yoshifumi Kadono
Overview
Explore the profile of Yoshifumi Kadono including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Shigehara K, Kato Y, Kawaguchi S, Izumi K, Kadono Y, Mizokami A
Curr Urol
. 2024 Sep;
18(3):199-202.
PMID: 39219636
Background: Only a few reports have currently studied the efficacy of dutasteride in patients with small benign prostatic hyperplasia (BPH). We investigated the efficacy of dutasteride on reducing lower urinary...
3.
Inaki A, Mizokami A, Wakabayashi H, Izumi K, Kadono Y, Toyama T, et al.
Ann Nucl Med
. 2024 May;
38(8):587-595.
PMID: 38750331
Background: Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals allow whole-body imaging to detect prostate cancer (PC). Positron emission tomography imaging using gallium-68 (Ga)-PSMA-11 has been shown to have a favorable safety and...
4.
Kano H, Kadono Y, Naito R, Makino T, Iwamoto H, Yaegashi H, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38610982
Background: The efficacy of intermittent androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP) is unknown, and its usefulness in Japanese practice needs to be investigated....
5.
Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339260
Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) can improve the survival of patients with castration-resistant prostate cancer (CRPC). However, the agent that is more effective against nonmetastatic CRPC remains unclear....
6.
Kano H, Izumi K, Nakagawa R, Toriumi R, Aoyama S, Kamijima T, et al.
Anticancer Res
. 2023 Sep;
43(10):4619-4626.
PMID: 37772589
Background/aim: The percentage of positive cores (PPC) is increasingly recognized as a prognostic factor in prostate cancer. However, the usefulness of PPC for patients undergoing androgen deprivation therapy (ADT) and...
7.
Shigehara K, Izumi K, Nakashima K, Kawaguchi S, Nohara T, Kadono Y, et al.
Transl Androl Urol
. 2023 Sep;
12(8):1273-1282.
PMID: 37680217
Background: The current study attempted to elucidate the mechanisms of keishibukuryogan (TJ-25) efficacy by focusing on hormonal and cytokine levels. This is a sub-analysis of serum hormonal and cytokine levels...
8.
Kato Y, Shigehara K, Nakagawa T, Kawaguchi S, Izumi K, Kadono Y, et al.
Health Sci Rep
. 2023 Aug;
6(8):e1496.
PMID: 37599654
Background And Aims: Testosterone deficiency is often related to geriatric syndrome including erectile dysfunction, osteo-porosis, depression, cognitive impairment, cardiovascular diseases and frailty. Despite the existence of many studies on short-term...
9.
10.
Kadono Y, Konaka H, Nohara T, Izumi K, Anai S, Fujimoto K, et al.
Cancers (Basel)
. 2023 Jun;
15(10).
PMID: 37345082
Background: The sequence of first-line cytokine and second-line molecular targeted therapies may be suitable for some patients with metastatic renal cell carcinoma (mRCC) because of the expectation of complete remission...